ClinicalTrials.gg
CompletedNCT05604781Updated Mar 18, 2024Results posted

Symfony/Synergy IOL Combination Outcomes

An observational study in Bilateral Cataract and Presbyopia, sponsored by Center For Sight. Completed at 2 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Center For Sight · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
41
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 456 studies in Cataract with a site in United States — 49 open to participants now, 56 under way, 4 of them phase 3. Cataract · United States.

Enrollment
83rd of 128
41 · median 61
Started
2022
with 27 others
Observational
128 of 456
19 open now
Registered
351st of 456
by date

Among the 456 studies in Cataract with a site in United States, this one is the 83rd largest by enrollment of the 128 observational ones that give a count, is one of 28 that started in 2022, is one of 128 observational ones, and was the 351st registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

49 of the 456 studies in Cataract with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 456 studies in Cataract with a site in United States, or all of them as a file.
02

Study summary

Current visual outcomes expectations of cataract patients are similar to those of refractive surgery patients. Their desire is to be spectacle independent for far, intermediate and near vision activities. Some may have already enjoyed freedom from glasses and would like to continue after the cataracts are removed. Different options are available. These options include: mono-vision and presbyopia correcting intraocular lenses (IOL). Presbyopia correcting IOLs include accommodative, multifocals and extended depth of focus (EDOF) IOLs. In a previous study that evaluated the visual outcomes of an EDOF IOL when combined with a multifocal IOL with a +3.25 D add in patients with or without astigmatism undergoing routine cataract surgery showed good outcomes with high patient satisfaction and less dependance on glasses for intermediate and near activities. As technology evolves, new lens models are available in the market. The purpose of this study is to evaluate the latest EDOF and a hybrid multifocal lenses when combined.

03

Conditions studied

  • Bilateral Cataract
  • Presbyopia
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients from two ophthalmology clinics.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is undergoing bilateral lens extraction with intraocular lens implantation of the Symfony with InteliLight in the dominant eye and a Synergy in the non-dominant eye.
  2. Gender: Males and Females.
  3. Age: 50 years and older.
  4. Willing and able to provide written for participation in the study
  5. Willing and able to comply with scheduled visits and other study procedures.
  6. Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes within 2 to 30 days between surgeries
  7. Subjects who require an IOL power in the range of +5.00 D to +34.0 D only.
  8. Subjects who require a toric IOL up to +3.75 D at the IOL plane (2.57 D corneal plane).
  9. Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both eyes.

Exclusion criteria

Exclusion Criteria:

  1. Severe preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, shallow anterior chamber, macular edema, retinal detachment, aniridia or iris atrophy, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmos or macrophthalmos, optic nerve atrophy, macular degeneration (with anticipated best postoperative visual acuity less than 20/30), advanced glaucomatous damage, etc.
  2. Uncontrolled diabetes.
  3. Use of any systemic or topical drug known to interfere with visual performance.
  4. Contact lens use during the active treatment portion of the trial.
  5. Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.
  6. corneal dystrophy
  7. History of chronic intraocular inflammation.
  8. History of retinal detachment.
  9. Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.
  10. Previous intraocular surgery.
  11. Previous corneal refractive surgery (i.e. LASIK, photorefractive keratectomy, radial keratotomy).
  12. Previous keratoplasty
  13. Severe dry eye
  14. Pupil abnormalities
  15. Anesthesia other than topical or peribulbar anesthesia (i.e. retrobulbar, general, etc).
  16. Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results.
  17. Participation in (or current participation) any ophthalmic drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
41 participants (actual)
Patient registry
No

Groups and cohorts

  • Symfony & Synergy IOL combination

    Device: Symfony & Synergy IOL combination

Interventions

  • DeviceSymfony & Synergy IOL combination

    The Symfony IOL will be implanted in the dominant eye while the Synergy IOL will be implanted in the non-dominant eye.

06

What researchers measure

Primary outcomes

  1. Binocular Defocus Curve

    Time frame: 3 months

Secondary outcomes

  1. Patient Satisfaction Questionnaire

    Percentage for participants who are completely or mostly satisfied with their overall vision will be assessed

    Time frame: 3 months

  2. Spectacle Independence for Near Activities Questionnaire

    Percentage of participants reporting the need to wear glasses all the time for near activities will be assessed.

    Time frame: 3 months

07

Results

Posted Mar 18, 2024

Participant flow

Participant flow — Overall Study
MilestoneSymfony & Synergy IOL Combination
Started41
Completed37
Not completed4
Withdrew: Lost to follow-up3
Withdrew: Adverse event1

Outcome measures

PrimaryBinocular Defocus Curve
Time frame:
3 months
Reported as:
Mean · logMAR
Binocular Defocus Curve
logMARSymfony & Synergy IOL Combination
+1.00 D0.07 ± 0.10
+0.50 D-0.05 ± 0.08
0.00 D-0.08 ± 0.12
-0.50 D-0.05 ± 0.09
-1.00 D-0.04 ± 0.10
-1.50 D-0.03 ± 0.13
-2.00 D0.04 ± 0.13
-2.50 D0.07 ± 0.14
-3.00 D0.14 ± 0.14
SecondaryPatient Satisfaction Questionnaire

Percentage for participants who are completely or mostly satisfied with their overall vision will be assessed

Time frame:
3 months
Reported as:
Count of participants · Participants
Patient Satisfaction Questionnaire
ParticipantsSymfony & Synergy IOL Combination
Patient Satisfaction Questionnaire31
SecondarySpectacle Independence for Near Activities Questionnaire

Percentage of participants reporting the need to wear glasses all the time for near activities will be assessed.

Time frame:
3 months
Reported as:
Count of participants · Participants
Spectacle Independence for Near Activities Questionnaire
ParticipantsSymfony & Synergy IOL Combination
Spectacle Independence for Near Activities Questionnaire4

Adverse events

Collected over 3 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Symfony & Synergy IOL Combination0/37 (0%)0/37 (0%)0/37 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Symfony & Synergy IOL Combination
Mean68.6 ± 6.3
Sex: Female, Male
Sex: Female, Male(Participants)Symfony & Synergy IOL Combination
Female27
Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Symfony & Synergy IOL Combination
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White37
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Symfony & Synergy IOL Combination
United States37
08

Study locations

2 sites
  • Center For Sight
    Venice, Florida 34285, United States
  • Helga Sandoval
    Mount Pleasant, South Carolina 29464, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in May 2023, 6 months.

Results were first posted in Mar 2024, 10 months after primary completion.

Of 169 non-industry observational studies under Cataract, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 30. This study's 6 months is below that.

Counting every sponsor, half of 236 studies reached it within 16 months; a quarter within 9 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Nov 3, 2022
StartActual
Oct 17, 2022
Primary completionActual
May 16, 2023
CompletionActual
May 16, 2023
Results first posted
Mar 18, 2024
Last update
Mar 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05604781
Lead sponsor
Center For Sight
Collaborators
Science in Vision
Responsible party
Sponsor
First posted
Nov 3, 2022
Start date
Oct 17, 2022
Primary completion
May 16, 2023
Completion
May 16, 2023
Results posted
Mar 18, 2024
Last update
Mar 18, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion